Alligator Sells the Lab, Keeps the Royalty — and Admits the Cash Runs Out Before the Check Arrives
A SEK 38 million market cap, SEK 41 million of cash, a 1.75% royalty that starts paying in 2030, and a CEO who is leaving at year-end
ATORX.ST · Earnings Call · 2026-10-22
The pivot is now the whole company
Alligator Bioscience has stopped being a drug developer. The Q3 2026 call is not a quarterly update so much as a corporate liquidation dressed as a strategy, and management is unusually candid about it. The mitazalimab programme — the asset the company spent years and hundreds of millions of kronor on — was discontinued for independent development in July, and the entire organisation is being wound down to a shell that holds one thing: a 35% share of AbClon's economics on HLX22, a HER2 antibody owned and developed by Shanghai Henlius Biotech.
Søren Bregenholt framed it plainly: “in July, Alligator announced that we would discontinue our independent development of mitazalimab and refocus the company on Alligator's financial interest in HLX22” — Søren Bregenholt, CEO · 2026-10-22. That financial interest is the whole equity story now, and it comes with a tidy arithmetic: “Altogether, these numbers give an effective royalty rate for Alligator of up to 1.75% of the net sales of HLX22, and Alligator will not incur any development costs” — Søren Bregenholt, CEO · 2026-10-22. No R&D burn, no trial risk, no CMC spend — just a royalty rate and a wait.
That wait is the problem. First topline Phase III readout in gastric cancer is guided to the second half of 2027, launch 18–24 months after that on management's cautious framing, and first royalty revenue the year after. Johan Giléus did not soften it:
depending on the outcome and depending on a few other things, I'm quite certain that we will not have enough money until we can see the first royalty income, and that is expected in 2030, so that's quite a long way.
Read that again. The CFO is telling shareholders the balance sheet does not bridge to the only cash flow the business will ever have. Everything else on the call — the rights issue, the warrants, the Fenja extension — is an attempt to buy time against that gap.
The bracket, and what is left unsaid
Management gave a royalty estimate of SEK 150–450 million annually at peak, and was explicit that this is Alligator's own guess, not Henlius guidance: they have no non-public information on pricing or launch. The low scenario assumes teens market share in gastric/gastroesophageal junction cancer and monoclonal-antibody-like global pricing, hitting the bottom of the range; a better-but-not-Phase-II-better scenario with up to 50% higher pricing reaches the middle. The full bracket of royalties rests on roughly 110,000 addressable HER2-positive patients a year.
The refusal to disclose the royalty ladder is the most contested point on the call, and Bregenholt was emphatic that it is contractual, not evasive — 35% of AbClon's up-to-5% is the legal limit of what they can say. Still, the market has clearly not done the work either. Asked why nobody wants the shares, the outgoing CEO offered: “why is nobody interested in buying your shares? I don't really have an answer for that” — Søren Bregenholt, CEO · 2026-10-22. That is a remarkable thing to say on a public earnings call, and a fair proxy for how the story is landing.
The cost base is the only lever left
The wind-down is real and quantified. Headcount has been given notice, the OPTIMIZE-1 study is in final close-out, and spring's Phase III ramp-up costs are still trailing through the P&L. Giléus put a target on the floor: “we will come down to in the region of SEK 1 million per month in running cost for that minimal organization, and that will be reached in the Q2 2027” — Johan Giléus, CFO · 2026-10-22. A minimal organization of roughly one executive and a board, running at SEK 12 million a year, is a fundamentally different security from the company that existed six months ago.
The financing stack is precarious and laddered. The bridge loan of SEK 19 million has been repaid from the rights issue; the issue was subscribed to the guaranteed SEK 58.8 million, with guarantors taking roughly 29–30%; the Fenja loan of SEK 6.6 million has been extended to 30 June 2027 with warrants attached; TO 15 exercises in January 2027 with pricing set mid-December to early January, and TO 16 a year later. Each of these is a small lifeline thrown just far enough to reach the next one. The runway question was asked directly and answered with a deferral: “we need to sort out the mitazalimab situation, as you mentioned before, and a few of the other wind downs so we have the clear understanding on where we are, and before I can do any predictions on the runway” — Johan Giléus, CFO · 2026-10-22. Investors will not get that number until Q4 — after the January exercise, conveniently.
The mispricing question worth asking
Here is the tension that makes this more than a slow-motion wind-down. Alligator holds roughly SEK 41 million of cash after repaying the bridge loan, against a market capitalisation of around SEK 38 million. The equity trades below the cash on the balance sheet, with a free option on a future royalty stream that management itself values at SEK 150–450 million a year at peak. Either the market believes the cash evaporates before 2030 — which the CFO has essentially confirmed — or it is assigning zero to the HLX22 economics and to Henlius's willingness to push the asset across breast, colorectal and pancreatic cancer indications.
There is also the option value nobody is pricing: a sale of mitazalimab or out-licensing of ALG.APV-527 and the antibody technologies under evaluation agreements. Bregenholt said deals are progressing but would be, in his words, more back-loaded than a traditional business development deal — a polite way of saying the consideration is contingent.
Against the global backdrop, this is a company-unique story, not a sector wave. The curated market keywords for the quarter are dominated by rate, tariff and AI-infrastructure themes; nothing in the broad tape corroborates or contradicts Alligator. The nearest conceptual neighbour is the generic strategic reassessment and future monetization opportunity language that shows up across the market this quarter — but Alligator is not riding that wave, it is being run over by it. The company-specific keyword set tells the story cleanly: HLX22, AbClon, Henlius, royalty, bracket, Fenja and runway are the fresh high-momentum terms in the quarter, while the old identity words — the ones about trial execution and pipeline — have simply stopped appearing.
What changed, and why it matters
For four quarters the market has watched Alligator talk financing. This quarter the strategy finally became coherent with the balance sheet: no more development spend, a one-person operating structure, and the entire enterprise value transferred into a contractual claim on somebody else's drug. That is a legitimate structure — royalty stubs exist and trade — but it requires patient capital with a 2030 horizon, and Alligator has neither the cash nor the evident investor base to supply it. The remaining catalysts are binary and distant: the Phase III topline data in H2 2027, the TO 15 exercise in January, and the eventual mitazalimab disposal. Between now and then, this is a company being kept alive on warrants and goodwill.
The leadership handoff — Bregenholt out at year-end, Giléus into the CEO seat — completes the picture. The person who sold the HLX22 thesis is leaving; the person who has to fund it is staying. For a name trading under its own cash, with a royalty that begins nine quarters after the money runs out, that is the only story left to tell.